An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
about
Beta-3 adrenergic receptor agonist for adult with overactive bladderEffect of renal or hepatic impairment on the pharmacokinetics of mirabegron.A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.Comparison of solifenacin and fesoterodine in treatment of overactive bladder.Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns AnalyzerUrinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.Evaluation of the Pharmacokinetic Interaction Between the β3 -Adrenoceptor Agonist Mirabegron and the Muscarinic Receptor Antagonist Solifenacin In Healthy Subjects.Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged ≥75 Years: Analysis of a Japanese Post-Marketing Study.Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
P2860
Q24187596-69E0A191-AAF0-4831-9DCF-15949A4FC5A2Q34645986-C954F3D3-CB0F-44DA-BCFE-7DF755CB33CDQ35548496-AFEA4300-1E42-4A5F-8BEA-00B1C22159B0Q36210264-59697D62-25C5-4961-98EE-5BA287B39DE1Q37432115-0711300D-1FF6-49D2-B45C-2040603057CCQ37441427-E12CAF13-A8EA-40AC-9AAD-A5FB6E35A3ECQ37466573-0665CD74-EB65-4B68-AF70-B614F28F16E7Q39816197-1083A15B-EEC9-49DC-977D-A816E59E541DQ42596957-FBAF563C-20B8-46A2-95C3-55FA55808CCCQ47993403-1070BFB3-99D7-4766-831A-886CA8C8C2AFQ48300325-7B518B95-598C-4528-9EB3-BE5AB5CF551DQ58765630-4D793D49-5224-4616-97BA-015BFEF2C17B
P2860
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
@en
type
label
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
@en
prefLabel
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
@en
P2860
P356
P1433
P1476
An overview of the clinical use of antimuscarinics in the treatment of overactive bladder
@en
P2093
Konstantinos Giannitsas
P2860
P304
P356
10.1155/2011/820816
P577
2011-06-07T00:00:00Z